Skip to content
Screener

G&A at other companies

Ocular Therapeutix logo
Ocular TherapeutixOCUL
$20.01M+22.4%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$11.23M-27.2%
Regenxbio logo
RegenxbioRGNX
$21.62M+8.7%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$11.69M-9.7%
KLR
Kalaris TherapeuticsKLRS
$4.26M-1.5%

Other financials

Income statement

See full
Revenue$507.0K-90.5%
Gross profit$9.8M-30.1%
Operating income-$97.4M-56.5%
Net income-$94.5M-59.0%
EPS (diluted)-$1.09-28.2%

Balance sheet

See full
Cash & equivalents$110.5M+55.3%
Total debt$22.4M-5.7%
Total equity$166.4M-32.4%
Total assets$228.2M-24.2%

Cash flow

See full
Operating cash flow-$62.3M+0.4%
CapEx$1.2M-1.6%
Free cash flow-$63.5M+0.4%

Valuation

See full
Market cap$1.2B+69.1%
Enterprise value$1.11B+67.9%
P/S429.4×+416×

Profitability

See full
Operating margin-11,365.2%-11,754pp
Net margin-10,994.7%-11,355pp
FCF margin-9,726.7%-10,132pp

Returns & leverage

See full
Return on equity-148.7%-13,871pp
Debt / equity0.1×0.0×
Current ratio4.5×-3.5×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: EyePoint, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335037
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Cost of sales165533970
Research and development83,61455,498155,757114,072
Sales and marketing31353470
General and administrative14,24211,86229,48525,738
Total operating expenses97,88767,560185,809140,850
Loss from operations(97,380)(62,227)(184,606)(111,064)
Other (expense) income:
Interest and other income, net2,9102,8945,2546,536

Item 1. Unaudited Financial Statements

FAQ

What is EyePoint, Inc.'s G&A?
EyePoint, Inc. (EYPT) reported G&A of $14.24M in Q2 2026.
How has EyePoint, Inc.'s G&A changed year-over-year?
EyePoint, Inc.'s G&A increased by 20.1% year-over-year, from $11.86M to $14.24M.
What is the long-term trend for EyePoint, Inc.'s G&A?
Over 4 years (2021 to 2025), EyePoint, Inc.'s G&A has grown at a 19.2% compound annual growth rate (CAGR), from $25.58M to $51.61M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Ask your AI about EyePoint, Inc.'s g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude